Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,753,640 shares of the biopharmaceutical company’s stock after selling 420,344 shares during the quarter. T. Rowe Price Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $697,335,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. First Horizon Corp boosted its stake in Alnylam Pharmaceuticals by 20.7% during the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 28 shares in the last quarter. Yousif Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 29 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. Finally, Everpar Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 6.3% in the fourth quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 37 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Down 1.6%

ALNY stock opened at $278.09 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The firm has a market capitalization of $37.13 billion, a P/E ratio of 75.98 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a 52-week low of $273.11 and a 52-week high of $495.55. The company’s 50 day simple moving average is $301.17 and its 200-day simple moving average is $338.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the business posted ($0.44) EPS. The company’s revenue was up 96.4% on a year-over-year basis. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on ALNY. Chardan Capital reaffirmed a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Truist Financial cut their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a report on Monday, April 13th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Jefferies Financial Group restated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Finally, Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at $3,120,156.06. This represents a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 7,740 shares of company stock valued at $2,420,214 in the last 90 days. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.